CA2382812A1 - Structures cristallines de domaines de proteines tyrosine kinases de recepteur et de leurs ligands - Google Patents
Structures cristallines de domaines de proteines tyrosine kinases de recepteur et de leurs ligands Download PDFInfo
- Publication number
- CA2382812A1 CA2382812A1 CA002382812A CA2382812A CA2382812A1 CA 2382812 A1 CA2382812 A1 CA 2382812A1 CA 002382812 A CA002382812 A CA 002382812A CA 2382812 A CA2382812 A CA 2382812A CA 2382812 A1 CA2382812 A1 CA 2382812A1
- Authority
- CA
- Canada
- Prior art keywords
- tyrosine kinase
- protein tyrosine
- receptor protein
- ligand
- crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne la détermination et l'utilisation de structures tridimensionnelles de protéines tyrosine kinases de récepteur (RPTK) et/ou de leurs ligands. Un groupe particulier de ces structures comprend des structures tridimensionnelles du domaine extracellulaire des RPTK. Les structures tridimensionnelles des RPTK peuvent faciliter la conception et l'identification de modulateurs de la fonction RPTK. D'autres structures de ce type peuvent comprendre des ligands RPTK, tels qu'un facteur de cellules souches ou un fragment de ce dernier. Les modulateurs de la fonction RPTK peuvent être utilisés pour traiter des maladies induites par une activité inappropriée de RPTK.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15181099P | 1999-08-30 | 1999-08-30 | |
US60/151,810 | 1999-08-30 | ||
PCT/US2000/023744 WO2001016181A2 (fr) | 1999-08-30 | 2000-08-30 | Structures cristallines de domaines de proteines tyrosine kinases de recepteur et de leurs ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2382812A1 true CA2382812A1 (fr) | 2001-03-08 |
Family
ID=22540331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002382812A Abandoned CA2382812A1 (fr) | 1999-08-30 | 2000-08-30 | Structures cristallines de domaines de proteines tyrosine kinases de recepteur et de leurs ligands |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1212365A2 (fr) |
JP (1) | JP2003513016A (fr) |
AU (1) | AU7087000A (fr) |
CA (1) | CA2382812A1 (fr) |
WO (1) | WO2001016181A2 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005508295A (ja) * | 2001-06-07 | 2005-03-31 | エフ.ホフマン−ラ ロシュ アーゲー | Igf結合タンパク質の変異体、およびそれらのアゴニストの作製法 |
JP2007520997A (ja) * | 2003-01-21 | 2007-08-02 | スミスクライン ビーチャム コーポレーション | ErbB4共結晶 |
US7303893B1 (en) | 2003-08-28 | 2007-12-04 | Takeda San Diego, Inc. | Crystallization of c-KIT tyrosine kinase leading to autoinhibited crystal structure |
JP5360738B2 (ja) * | 2008-03-03 | 2013-12-04 | 国立大学法人 奈良先端科学技術大学院大学 | 細胞増殖促進活性を有するペプチド |
CN104177492B (zh) * | 2014-07-21 | 2017-02-22 | 暨南大学 | FGFR2c胞外段类似物及其编码基因与应用 |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
WO2018152326A1 (fr) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Polypeptides de liaison au récepteur de transferrine modifiés |
EP3612234B1 (fr) | 2017-04-20 | 2024-03-13 | ADC Therapeutics SA | Polythérapie avec un conjugué anticorps anti-axl-médicament |
SI3665192T1 (sl) * | 2017-08-10 | 2023-11-30 | Denali Therapeutics Inc. | Inženiring polipeptidov, ki se vežejo na receptorje za transferine |
CN115746111A (zh) * | 2021-09-02 | 2023-03-07 | 中国科学院天津工业生物技术研究所 | 一种转录调控因子LysG的突变体及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001514484A (ja) * | 1996-08-21 | 2001-09-11 | スージェン・インコーポレーテッド | タンパク質チロシンキナーゼの結晶構造 |
-
2000
- 2000-08-30 EP EP00959577A patent/EP1212365A2/fr not_active Withdrawn
- 2000-08-30 AU AU70870/00A patent/AU7087000A/en not_active Abandoned
- 2000-08-30 CA CA002382812A patent/CA2382812A1/fr not_active Abandoned
- 2000-08-30 WO PCT/US2000/023744 patent/WO2001016181A2/fr active Application Filing
- 2000-08-30 JP JP2001520740A patent/JP2003513016A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2001016181A2 (fr) | 2001-03-08 |
EP1212365A2 (fr) | 2002-06-12 |
AU7087000A (en) | 2001-03-26 |
WO2001016181A3 (fr) | 2002-01-24 |
JP2003513016A (ja) | 2003-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7129072B1 (en) | Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor | |
WO1998007835A2 (fr) | Structures cristallines d'une proteine tyrosine kinase | |
Wybenga-Groot et al. | Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region | |
Tesmer et al. | Structure of RGS4 bound to AlF4−-activated Giα1: stabilization of the transition state for GTP hydrolysis | |
Jeffery et al. | Crystal structure of rabbit phosphoglucose isomerase, a glycolytic enzyme that moonlights as neuroleukin, autocrine motility factor, and differentiation mediator | |
Kim et al. | Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866 | |
Lu et al. | Crystal structure of human epidermal growth factor and its dimerization | |
Bennett et al. | Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor | |
Iyer et al. | The crystal structure of human placenta growth factor-1 (PlGF-1), an angiogenic protein, at 2.0 Å resolution | |
Brown et al. | Structure of a functional IGF2R fragment determined from the anomalous scattering of sulfur | |
Yeh et al. | Structural basis for activation of fibroblast growth factor signaling by sucrose octasulfate | |
US8338573B2 (en) | Crystal structure of CD147 extracellular region and use thereof | |
US20050187150A1 (en) | Structure-based design and synthesis of FGF inhibitors and FGF modulator compounds | |
CA2382812A1 (fr) | Structures cristallines de domaines de proteines tyrosine kinases de recepteur et de leurs ligands | |
US7754458B2 (en) | Crystal structure of the complex of hepatocyte growth factor beta chain with met receptor and methods of use | |
Ishino et al. | Kinetic interaction analysis of human interleukin 5 receptor α mutants reveals a unique binding topology and charge distribution for cytokine recognition | |
CA2476006A1 (fr) | Complexe egf/egfr | |
US7294706B2 (en) | Identification of receptor and heparin binding sites in FGF4 by structure-based mutagenesis | |
Patel et al. | The three-dimensional structure of MAP kinase p38β: different features of the ATP-binding site in p38β compared with p38α | |
Paul et al. | Glycal formation in crystals of uridine phosphorylase | |
US7491731B2 (en) | Crystal structure of liganded cFMS kinase domain | |
US20040132634A1 (en) | Compositions and methods for regulating the kinase domain of receptor tyrosine kinases | |
Chen et al. | Phospho-priming confers functionally relevant specificities for Rad53 kinase autophosphorylation | |
Inniss et al. | Discovery of a Druggable, Cryptic Pocket in SARS-CoV-2 nsp16 Using Allosteric Inhibitors | |
US7584087B2 (en) | Structure of protein kinase C theta |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20090831 |